StockData
Nautilus Biotechnology, Inc. logo

Nautilus Biotechnology, Inc. (NAUT) stock

NAUTNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 6/30
$2.36+0.26 (+12.38%)

Close on Nov 17, 2026Market cap $300.60MP/E –Yield –

Nautilus Biotechnology cash

Cash and short-term investments held at the end of each period.

Nautilus Biotechnology's cash was $114.30M at Sep 30, 2026. For fiscal 2025 it was $103.40M, down 20.4% from the year before. The highest annual figure on record is $345.70M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$103.40M-20.4%
FY2024Dec 31, 2024$129.90M-25.1%
FY2023Dec 31, 2023$173.40M-6.0%
FY2022Dec 31, 2022$184.50M-46.6%
FY2021Dec 31, 2021$345.70M+346.9%
FY2020Dec 31, 2020$77.35M+12900.7%
FY2019Dec 31, 2019$595.00K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$114.30M-13.0%
Q2 FY2026Jun 30, 2026$84.00M-43.2%
Q1 FY2026Mar 31, 2026$95.90M-30.9%
Q4 FY2025Dec 31, 2025$103.40M-20.4%
Q3 FY2025Sep 30, 2025$131.40M-6.5%
Q2 FY2025Jun 30, 2025$147.90M-11.6%
Q1 FY2025Mar 31, 2025$138.80M-23.5%
Q4 FY2024Dec 31, 2024$129.90M-25.1%
Q3 FY2024Sep 30, 2024$140.60M-23.3%
Q2 FY2024Jun 30, 2024$167.40M+2.5%
Q1 FY2024Mar 31, 2024$181.40M+8.4%
Q4 FY2023Dec 31, 2023$173.40M-6.0%
Q3 FY2023Sep 30, 2023$183.30M-29.0%
Q2 FY2023Jun 30, 2023$163.30M-45.4%
Q1 FY2023Mar 31, 2023$167.30M-48.4%
Q4 FY2022Dec 31, 2022$184.50M-46.6%
Q3 FY2022Sep 30, 2022$258.00M-25.7%
Q2 FY2022Jun 30, 2022$299.30M-19.8%
Q1 FY2022Mar 31, 2022$324.10M+518.3%
Q4 FY2021Dec 31, 2021$345.70M+346.9%
Q3 FY2021Sep 30, 2021$347.30M+2523.1%
Q2 FY2021Jun 30, 2021$373.10M+1035.0%
Q1 FY2021Mar 31, 2021$52.42M–
Q4 FY2020Dec 31, 2020$77.35M+12900.7%
Q3 FY2020Sep 30, 2020$13.24M–
Q2 FY2020Jun 30, 2020$32.87M–
Q1 FY2020Mar 26, 2020$0–
Q4 FY2019Dec 31, 2019$595.00K–

More Nautilus Biotechnology figures

See a number that looks wrong?